uniQure N.V.

NASDAQ:QURE

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Investing News NetworkYour trusted source for investing success

Top 10 Copper-producing Companies (Updated 2024)

Could the Silver Price Really Hit US$100 per Ounce? (Updated 2024)

Where Does Tesla Get its Lithium? (Updated 2024)

Rare Earths Reserves: Top 8 Countries (Updated 2024)

Hydrogen Stocks: 9 Biggest Companies

Top 10 Countries for Natural Gas Production (Updated 2024)

Top 5 Junior Gold Stocks on the TSXV in 2024

A State-by-State Guide to Cannabis in Australia

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Indicative, Conditional and Non-Binding Proposal Received by American Rare Earths

Beyond Lithium and Its Exploration Team Recognized with Bernie Schnieders Discovery of the Year Award

Freegold Announces Start of 2024 Drilling Program at Golden Summit

Elixir Energy Limited (ASX: EXR) – Trading Halt

Purepoint Uranium Group Inc. Launches Strategic Drill Program at Turnor Lake Project Targeting the La Rocque Structural Corridor

Falco Resources: Canadian Explorer in the Rouyn-Noranda Mining Camp

Jindalee Lithium

Elixir Energy

Forward Water Technologies

Rio Silver

2024 Gold Outlook Report

Lithium Outlook for Australia

2024 Uranium Outlook (Updated for Q2)

2024 Lithium Market Outlook

Manuka Resources March 2024 Quarterly Activities Report

Eclipse Metals Quarterly Activities Report and Appendix 5B

Mining Exploration Entity or Oil and Gas Exploration Entity Quarterly Cash Flow Report

True North Copper March 2024 Quarterly Report

Metals Australia Quarterly Activities Report - to 31 March 2024

uniQure N.V.